J. Baselga

1.3k total citations
25 papers, 649 citations indexed

About

J. Baselga is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, J. Baselga has authored 25 papers receiving a total of 649 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in J. Baselga's work include HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (7 papers) and Breast Cancer Treatment Studies (6 papers). J. Baselga is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (7 papers) and Breast Cancer Treatment Studies (6 papers). J. Baselga collaborates with scholars based in Spain, United States and Germany. J. Baselga's co-authors include Joaquı́n Arribas, María Borrell-Pagés, Federico Rojo, Joan Albanell, Yoshiaki Uchida, Govind Panchamoorthy, Hasan Rajabi, Donald Küfe, C Jin and Maurizio Scaltriti and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

J. Baselga

23 papers receiving 640 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Baselga Spain	10	399	312	188	139	98	25	649
B. Lisboa Germany	12	474 1.2×	203 0.7×	376 2.0×	100 0.7×	97 1.0×	23	788
Christina V. Obiezu Canada	14	285 0.7×	303 1.0×	122 0.6×	193 1.4×	46 0.5×	16	1.0k
Kristin Gurtner Germany	11	266 0.7×	256 0.8×	165 0.9×	188 1.4×	91 0.9×	16	595
Khoi Chu United States	15	468 1.2×	432 1.4×	188 1.0×	218 1.6×	66 0.7×	22	869
Lisa E. Humphrey United States	17	442 1.1×	498 1.6×	112 0.6×	100 0.7×	57 0.6×	23	783
P.M.J.J. Berns Netherlands	8	463 1.2×	283 0.9×	168 0.9×	151 1.1×	158 1.6×	13	714
Carmine Fedele United States	12	280 0.7×	628 2.0×	214 1.1×	142 1.0×	69 0.7×	16	870
Laura Vízkeleti Hungary	14	367 0.9×	365 1.2×	180 1.0×	91 0.7×	40 0.4×	33	622
Jennie Hauser United States	9	235 0.6×	332 1.1×	94 0.5×	85 0.6×	38 0.4×	13	542
Barbara Dunne United Kingdom	12	482 1.2×	536 1.7×	230 1.2×	172 1.2×	98 1.0×	21	973

Countries citing papers authored by J. Baselga

Since Specialization

Citations

This map shows the geographic impact of J. Baselga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Baselga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Baselga more than expected).

Fields of papers citing papers by J. Baselga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Baselga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Baselga. The network helps show where J. Baselga may publish in the future.

Co-authorship network of co-authors of J. Baselga

This figure shows the co-authorship network connecting the top 25 collaborators of J. Baselga. A scholar is included among the top collaborators of J. Baselga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Baselga. J. Baselga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Prat, Aleix, Yufeng Cheng, Paolo Nucíforo, et al.. (2018). PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. European Journal of Cancer. 92. S117–S118. 3 indexed citations

Shi, Wenhao, Tingting Jiang, Paolo Nucíforo, et al.. (2016). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of Oncology. 28(1). 128–135. 51 indexed citations

Prat, Aleix, Victoria Ortega, Laia Paré, et al.. (2016). Abstract P3-07-66: Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study. Cancer Research. 76(4_Supplement). P3–7. 1 indexed citations

Brastianos, Priscilla K., Sandro Santagata, Daniel P. Cahill, et al.. (2015). 2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets. European Journal of Cancer. 51. S586–S586. 6 indexed citations

Raina, Deepak, Yoshiaki Uchida, Akriti Kharbanda, et al.. (2013). Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 33(26). 3422–3431. 95 indexed citations

Isakoff, SJ, Cristina Cruz, J. E. Garber, et al.. (2013). Abstract OT1-4-01: Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC). Cancer Research. 73(24_Supplement). OT1–4. 1 indexed citations

Baselga, J., Mario Campone, Martine Piccart, et al.. (2011). Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial.. Journal of Clinical Oncology. 29(15_suppl). e11058–e11058. 2 indexed citations

Baselga, J.. (2009). S43 Review of new targeted drugs: Crawling towards the adjuvant setting. The Breast. 18. S17–S18. 1 indexed citations

Cervantes, Andrés, Teresa Macarulla, Susana Roselló, et al.. (2008). 279 POSTER MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial. European Journal of Cancer Supplements. 6(12). 90–90. 4 indexed citations

10.

Gianni, Lorenzo, W. Eiermann, L. Pusztai, et al.. (2008). Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC). Journal of Clinical Oncology. 26(15_suppl). 504–504. 10 indexed citations

11.

Prat, Aleix & J. Baselga. (2007). Bioterapia: aplicaciones actuales y futuras en oncología. Medicina Clínica. 129(5). 184–193. 2 indexed citations

12.

Chandarlapaty, Sarat, et al.. (2007). Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer. Journal of Clinical Oncology. 25(18_suppl). 10515–10515. 4 indexed citations

13.

Gianni, Lorenzo, J. Baselga, W. Eiermann, et al.. (2005). European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). Journal of Clinical Oncology. 23(16_suppl). 513–513. 44 indexed citations

14.

Carpenter, J., H. Roché, Mario Campone, et al.. (2005). Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 564–564. 81 indexed citations

15.

Bech‐Serra, Joan Josep, et al.. (2004). Inactivating mutations block the tumor necrosis factor-α-converting enzyme in the early secretory pathway. Biochemical and Biophysical Research Communications. 314(4). 1028–1035. 17 indexed citations

16.

Trigo, José, Ricardo Hitt, P. Koralewski, et al.. (2004). Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. Journal of Clinical Oncology. 22(14_suppl). 5502–5502. 26 indexed citations

17.

Graeven, U., Steffen C. Hinz, Wolfram von Bernstorff, et al.. (2004). Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer. Journal of Clinical Oncology. 22(14_suppl). 3061–3061. 4 indexed citations

18.

Borroto, Aldo, María Borrell-Pagés, Anna Merlos‐Suárez, et al.. (2003). Impaired Trafficking and Activation of Tumor Necrosis Factor-α-converting Enzyme in Cell Mutants Defective in Protein Ectodomain Shedding. Journal of Biological Chemistry. 278(28). 25933–25939. 42 indexed citations

19.

Borrell-Pagés, María, Federico Rojo, Joan Albanell, J. Baselga, & Joaquı́n Arribas. (2003). TACE is required for the activation of the EGFR by TGF-α in tumors. The EMBO Journal. 22(5). 1114–1124. 238 indexed citations

20.

Baselga, J.. (2001). Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy. The Oncologist. 6(90003). 26–29. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact